Other diseases
Spinal muscular atrophy
脊髓性肌萎缩症
A group of inherited disorders with progressive muscle wasting and low muscle tone. The paper search uses the childhood-onset MeSH heading.
Definition adapted from MeSH (US National Library of Medicine)
- hospitals in mainland China
- 51
- cities
- 26
with a paper from 2016–2025 or a registered study
where those hospitals are
Mainland China accounts for 11% of the world's English-language research papers on spinal muscular atrophy, 2021–2025 (8% in 2016–2020), and 10% of the world's registered trials on it have a site in China.
Research activity in public records, not a rating of care and not medical advice. How the numbers are made
51 hospitals in 26 cities
Order: papers led on spinal muscular atrophy, 2021–2025, then A–Z. Research activity, not a rating of care.
A hospital is listed when it led at least 1 papers or 1 trial on spinal muscular atrophy, or was a site in 1 or more trials. “Papers led” counts English-language PubMed papers whose first or last author lists the hospital first. Hospitals not listed may also treat it. Definitions
Cities with the most listed hospitals
Each opens spinal muscular atrophy in that city. 16 more cities are in the menu below.
- 11 papers ledNo open trial led
- 4 papers ledNo open trial led
- 4 papers ledNo open trial led
- 3 papers ledNo open trial led
- 3 papers led
- 2 papers ledNo open trial led
- 2 papers ledNo open trial led
- 2 papers ledNo open trial led
- 2 papers ledNo open trial led
- 2 papers ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
No listed hospital matches these filters.
By university or health system 14
Hospitals carrying a university’s name, added together, plus papers that name only the university. Same order as above.
- 16 papers led2 hospitals
- 4 papers led1 hospital
- 4 papers led1 hospital
- 4 papers led1 hospital
- 3 papers led2 hospitals
- 2 papers led1 hospital
- 2 papers led1 hospital
- 2 papers led1 hospital
- 1 paper led1 hospital
- 1 paper led1 hospital
- 1 paper led1 hospital
- 0 papers led0 hospitals
- 0 papers led0 hospitals
- 0 papers led0 hospitals
open trials on spinal muscular atrophy in China
Recruiting, not yet recruiting, or by invitation, as registered on ClinicalTrials.gov on 13 Nov 2026, with at least one listed hospital as lead sponsor or site, and at least one listed hospital's site marked open. 3 of them are led by a listed hospital. Check the registry for the current status. Whether someone can take part is decided by the study team.
Trials registered only in China’s own registry (ChiCTR) are not included. Questions to check before asking about a trial
What the phases mean (US National Cancer Institute)
- RecruitingA Study to Learn About Salanersen's (BIIB115) Effects on Movement and Its Safety When Given Before Symptoms Appear in Babies With Genetically Diagnosed Spinal Muscular Atrophy (SMA)
- Phase
- Phase 3
- Started
- 2026-04
- Registry
- NCT07221669
Age 0 days to 42 days (registered criteria)
Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesShanghai, Zhengzhou
- RecruitingA Study to Learn About Salanersen's (BIIB115) Effects on Movement and Its Safety in Participants Aged 15 to 60 Years With Spinal Muscular Atrophy (SMA) Who Are Either New to SMA Treatment or Were Previously Treated With Risdiplam
- Phase
- Phase 3
- Started
- 2026-09
- Registry
- NCT07444476
Age 15 years to 60 years (registered criteria)
Led by Peking Union Medical College HospitalBeijing
- RecruitingA Phase I/II Clinical Study to Evaluate SKG0201 Injection in Subjects With Spinal Muscular Atrophy Type I
- Phase
- Phase 1/Phase 2
- Started
- 2026-07
- Registry
- NCT07554924
Age Not stated to 180 days (registered criteria)
Lead sponsor is not a listed hospital; 3 listed hospitals as study sitesBeijing, Hangzhou, Shanghai
- RecruitingEffects of Different Stiffness Settings During Robotic Isokinetic Training in Children With SMA
- Phase
- N/A
- Started
- 2026-10
- Registry
- NCT07822711
Age 6 years to 12 years (registered criteria)
Led by Peking University Third HospitalBeijing
- RecruitingSafety and Efficacy Evaluation of GC101 Gene Therapy Via Intrathecal (IT) Injectionin the Treatment of Patients With Type 2 Spinal Muscular Atrophy (SMA) - Phase III
- Phase
- Phase 3
- Started
- 2025-05
- Registry
- NCT06971094
Age 2 years to 12 years (registered criteria)
Lead sponsor is not a listed hospital; 6 listed hospitals as study sitesBeijing, Shenzhen, Suzhou, Wuhan
- RecruitingEvaluation of Safety and Efficacy of Gene Therapy Drug in the Treatment of Spinal Muscular Atrophy (SMA) Type 3 Patients
- Phase
- Phase 1/Phase 2
- Started
- 2024-05
- Registry
- NCT06421831
Age 2 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing
- RecruitingEvaluation of Safety and Efficacy of Gene Therapy Drug in the Treatment of Spinal Muscular Atrophy (SMA) Type 1 Patients
- Phase
- Phase 1/Phase 2
- Started
- 2023-02
- Registry
- NCT05824169
Age 0 months to 6 months (registered criteria)
Lead sponsor is not a listed hospital; 3 listed hospitals as study sitesBeijing, Shenyang, Suzhou
- RecruitingA Registered Cohort Study on SMA
- Phase
- Not given
- Started
- 2019-07
- Registry
- NCT04010604
Age 1 week to 70 years (registered criteria)
Led by First Affiliated Hospital of Fujian Medical UniversityFuzhou
Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.
Before contacting a hospital
The same for every disease, so it is kept on one page. Each hospital page also has an enquiry letter in English and Chinese, and a name card to show staff.
- How to startTalk with the treating doctor, prepare the records hospitals ask for, then write to two or three hospitals.
- Questions to check before asking about a trialWhat the registered criteria usually ask about, and what to ask the study team.
- Common questionsInternational patients, costs, trials and visas.
Where these numbers come from
Papers
55 English-language PubMed papers on spinal muscular atrophy with an author in mainland China, 2021–2025; a hospital led a paper when its first or last author lists it first. Run the PubMed search
Trials
ClinicalTrials.gov records with a listed hospital as lead sponsor or site, as of 13 Nov 2026. ChiCTR is not included. Search ClinicalTrials.gov
Locations
Locations are shown at city centres. Check the hospital’s website for its address.